

MEDICAL SYSTEM NETWORK Co., Ltd.

First Quarter of Fiscal Year Ending March 2026

Earnings Report

Standard Market of Tokyo Stock Exchange;

Securities Code: 4350



About contents covered

- * The contents of this report pertaining future earnings described are based on information the company has held, and on certain assumptions supervising rational judgement, and are not what the company promises to achieve. There are numerous factors that may cause actual earnings to differ. Caution is given to the accuracy of information, and we do not take responsibility for loss etc., as a result of misinformed information.
- * Furthermore, this report is not prepared for the purposes of investment solicitation. Readers are responsible for their own judgement in any decision regarding investments.

Please see the following link for our English information.



https://www.msnw.co.jp/eng/

FY3/2026 1Q: Topics and Business Overview



Net Sales

YoY change

Progress rate vs. FY

31.10 billion yen

+5.7% (+1.68 billion yen)

24.8%

Operating Profit

YoY change

Progress rate vs. FY

0.43 billion yen

-6.1% (-0.028 billion yen)

12.9%

Net sales increased year-on-year and progressing largely according to plan.

- Saw contributions from newly opened pharmacies in the previous fiscal year in the Community Pharmacy Business.
 - No. of prescriptions at all pharmacies: +1.0% YoY change
- Steady expansion of business partners in the Pharmaceutical Manufacturing and Distribution Business.
 - No. of transacting pharmacies: 135.2% YoY growth rate

Although profit decreased due to wage increases and other factors, prescription unit prices exceeded the plan, and profits at each level exceeded our plan.

- Operating profit achieved 156.6% of the first quarter plan.
 - Unit price of prescriptions at existing pharmacies:
 +5.9% compared to plan

Community Pharmacy Network Segment

• Community Pharmacy 462 pharmacies (+5)

• Prescription Unit price(All pharmacies) 10,370 yen(+343 yen)*

• No. of prescriptions (All pharmacies) 2,505 K(+1.0%)*

No. of prescriptions (Existing pharmacies)
 2,407 K(-1.3%)*

~ Pharmacy Support Businesses ~

< Pharmaceutical Network Business >

• No. of affiliates (+261)

< Manufacture and Market Pharmaceuticals Business >

No. of ingredients
No. of products
52 ingredients (+3)*
120 products (+7)*

No. of affiliates
 6,993 affiliates (+1,822)**

< Pharmaceutical Logistics Business >

• No. of affiliates **2,408** affiliates (+836)

< Digital Shift Business >

• No. Installed pharmacies 6,226 pharmacies (+206)

Leasing and Facility related Segment

< Wisteria >

Occupancy rate of all 4 facilities

87.8% (-2.4%)


The figures in brackets indicate the change from the end of the previous FY * YoY

** No. of affiliates that have actually transacted business since April of each year

Table of Contents



Earnings Highlight	•••	5
Core strategies, Business Summary	• • •	10
Earnings Forecast for FY3/2026		20
Reference Materials		23



FY3/2026 1Q : Consolidated Results



(Unit: million yen)	FY3/2025 FY3/2026 YoY		οY	FY3/2026		FY3/2026	
The second line is profit margin	1Q (Results)	1Q (Results)	Change	Change (%)	Full year forecast	Progress rate	vs. 1Q plan
Net Sales	29,419	31,100	+1,680	+5.7%	125,500	24.8%	+3.9%
EBITDA *	1,278 4.3%	1,281 4.1%	+2	+0.2%	6890 5.5%	10.070	_
Operating Profit	468 1.6%	439 1.4%	(28)	(6.1%)	3,400 2.7%		+56.6%
Ordinary Profit	468 1.6%	404 1.3%	(63)	(13.6%)	3,200 _{2.5%}	,	+76.2%
Profit attributable to owners of parent	170 _{0.6%}	78 0.3%	(92)	(54.0%)	1,300	01170	+17,641.2%
Earnings per share (Yen)	5.85	2.69	(3.16)	_	44.48	_	_

^{*} Calculated as "Operating income + Depreciation and amortization + Amortization of goodwill"

FY3/2026 1Q: Results by Segment



■ Ne	t Sales (Unit: million yen)	FY3/2025 1Q (Results)	FY3/2026 1Q (Results)	Change	Change (%)
Net S	Sales	29,419	31,100	+1,680	+5.7%
	Community Pharmacy Network Segment *	28,029	29,850	+1,820	+6.5%
	Leasing and Facility Related Segment Meals Catering Segment Home Visit Nursing Segment	1,614	1,415	(198)	(12.3%)
	Adjustments	(224)	(165)	+58	_
■ Ор	erating Profit (Unit: million yen)	The second line is profit i	margin		
Segm	nent Profit	468 1.6%	439 1.4%	(28) (0.2pt)	(6.1%)
	Community Pharmacy Network Segment *	1,061 3.8%	1,065 3.6%	+3 (0.2pt)	+0.3%
	Leasing and Facility Related Segment Meals Catering Segment Home Visit Nursing Segment	46 2.9%	16 1.2%	(29) (1.7pt)	(63.2%)
	Adjustments	(639) -	(642)	(3)	_

^{*} Community Pharmacy Business, Pharmacy Support Businesses (Pharmaceutical Network Business, Pharmaceutical Manufacturing and Distribution Business, Pharmaceutical Logistics Business, Digital Shift Business)

FY3/2026 1Q: Consolidated Balance Sheet



■End of FY3/2025

(Unit: million yen)

■End of FY3/2026 1Q

(Unit: million yen)

,				
Assets	70,586	Liabilities	54,241	
Current assets	22,627	Current liabilities	24,377	
Cash and deposits	8,461	Short-term loans *	6,184	
		Fixed liabilities	29,863	
Fixed assets	47,959	Long-term loans	18,085	
Tangible fixed assets	28,473	Net assets	16,345	
Intangible fixed assets	9,908	Share capital	2,128	
Goodwill	9,063	Capital surplus	946	
Investments and other assets	9,578	Retained earnings	14,001	
		Treasury shares	(891)	
Total assets	70,586	Total liabilities and net assets	70,586	
Equity ratio				
(Equity ratio with taking into account net cash **				

	110 011 10/2020 10			
Assets	71,775	Liabilities	55,518	
Current assets	23,985	Current liabilities	26,896	
Cash and deposits	8,742	Short-term loans *	8,234	
		Fixed liabilities	28,622	
Fixed assets	47,789	Long-term loans	16,777	
Tangible fixed assets	28,632	Net assets	16,256	
Intangible fixed assets	9,742	Share capital	2,128	
Goodwill	8,860	Capital surplus	946	
Investments and other assets	9,414	Retained earnings	13,901	
		Treasury shares	(891)	
Total assets	71,775	Total liabilities and net assets	71,775	
Equity ratio				
Equity ratio with taking into account net cash **				

^{*} Includes long-term loans that will be repaid within one year

^{**} Own capital / (Total assets - Cash and deposits)


FY3/2026 1Q: Consolidated Cash Flows




Cashflows from operating activities 691 million yen	EBITDA * Payment of income taxes Changes in working capital	1,281 million yen (869 million yen) 313 million yen
Cashflows from investing activities (842 million yen)	Opening of new pharmacies costs Existing pharmacies renovation costs, etc. Repayment of guarantee deposits	(817 million yen) (292 million yen) 271 million yen
Cashflows from financing activities 462 million yen	Increase in short-term loans payable Repayment of lease obligations Payment of dividends Repayment of long-term loans payable	2,159 million yen (118 million yen) (162 million yen) (1,418 million yen)

^{*} Calculated by "operating profit + depreciation + amortization of goodwill"

■FY3/2025 1Q (Unit: million yen)










Core Strategies for the FY3/2026




Se	egments	Core Strategies and Numerical Targets		
	Community Pharmacy Business	 Foster a stronger medical mindset and provide high-quality drug treatment Existing store prescription volume +2.4% YoY 25 pharmacy openings, mainly in medical malls, 10 doctor invitations Increased productivity through appropriate cost controls 		
	- Pharmacy Suppor	rt Businesses -		
Community Pharmacy Network	Pharmaceuticals Network Business	 12,000 affiliates at the end of March 2026 (+997) Promote distribution improvement (deliver once a day on weekdays, no deliveries on Saturdays, and reduce urgent deliveries) Expansion of services (training & new service dev.) Building area networks (shared inventory system) 		
	Manufacture and Market Pharmaceuticals Business	 Maintaining stable supply Increasing the No. of transacting pharmacies end of fiscal year: 9,000 (+1,819) 		
	Pharmaceutical Logistics	 Maintaining stable supply Increasing the No. of transacting pharmacies At the end of fiscal year: 3,700 (+2,128) 		
	Digital Shift Business	 Onboarded pharmacies 6,850 by the end of March 2026 (+830) Continued enhancement of functionality 		
	nd Facility related egment	 Achieved 91.8% (+1.6pt) occupancy rate and stable operation in Wisteria Profitability improvement (measures against rising rents, management costs, and inflation) 		
	ering Segment, Nursing Segment			
	inance, ealth Management	 Company-wide implementation of cost control Ensure profitability and strengthen capital base 		

[Pharmacies openings and target number of pharmacies]




[Generic drug purchases by network affiliates]



Community Pharmacy Business: Trends in No. of Pharmacies




6 new outlets since the end of the previous FY. Acquired 1 outlet through M&A, 2 outlets closed or transferred business. As of the end 1Q, the number of pipeline locations connected to Medical Institutions exceeded the full year plan.



Community Pharmacy Business: Monthly Dispensing Fee (YoY)






^{*} Existing pharmacies: Pharmacies that have been continuously open since April 1, 2023 for the previous fiscal year and since April 1, 2024 for the current fiscal year.

Community Pharmacy Business:





Although the number of prescriptions at existing pharmacies decreased, the unit price of prescriptions rose significantly due to an increase in the number of high-cost pharmaceuticals.



Community Pharmacy Business: Dispensing Fee Breakdown



■ All pharm	acies	FY3/2025 1Q	FY3/2026 1Q	Change	Change (%)
No. c	of prescriptions (1,000)	2,481	2,505	+24	+1.0%
	Drug charge per prescription	7,640	7,874	+234	+3.1%
Unit price (yen)	Technical fee per prescription	2,387	2,496	+109	+4.6%
	Total	10,027	10,370	+343	+3.4%
Dispe	nsing fee (million yen) *	24,878	25,979	+1,101	+4.4%

■ Existing pharmacies

No. o	f prescriptions (1,000)	2,439	2,407	(32)	(1.3%)
	Drug charge per prescription	7,615	7,860	+246	+3.2%
Unit price (yen)	Technical fee per prescription	2,389	2,510	+121	+5.1%
	Total	10,004	10,371	+367	+3.7%
Dispensing fee (million yen) *		24,406	24,966	+560	+2.3%

^{*} Dispensing fees: calculated by number of prescriptions x unit price of prescriptions

Pharmacy Support Businesses*: Performance Summary



Through our efforts to expand business partnerships, the number of partner stores has grown steadily.

■ Progress against numerical targets for FY 2026/3


	FY 2026/3 Numerical Targets	Progress (As of June 30)		
Pharmaceutical Network Business	12,000 affiliates +997 affiliates (From the end of the previous FY)	11,264 affiliates +261 affiliates (From the end of the previous FY) 11,330 affiliates (As of July 31)		
Pharmaceutical Manufacturing and Distribution Business	9,000 transacting pharmacies +1,819 pharmacies (From the end of the previous FY)	6,993 transacting pharmacies ** +1,822 pharmacies (YoY) ** No. of transacting pharmacies is total pharmacies that have actually transacted business since April of each year.		
Pharmaceutical Logistics Business	3,700 transacting pharmacies +2,128 pharmacies (From the end of the previous FY)	2,408 transacting pharmacies +836 pharmacies (From the end of the previous FY)		
Digital Shift Business	6,850 installed pharmacies +830 pharmacies (From the end of the previous FY)	6,226 installed pharmacies +206 pharmacies (From the end of the previous FY)		


^{*} Pharmaceutical Network Business, Pharmaceutical Manufacturing and Distribution Business, Pharmaceutical Logistics Business, Digital Shift Business

Pharmaceuticals Network Business



The number of affiliates increased by 261 compared to the end of the previous fiscal year to reach 11,264.





■FY3/2026 Breakdown of Network affiliates

(unit No. of affiliates)

	1Q	Post a large increase last year on the back of
New	400	Post a large increase last year on the back of price revisions, albeit smaller, the increase in the number of affiliates is proceeding well.
Withdrawal	(139)	the number of affiliates is proceeding well.

(Reference) FY3/2025

	1 Q	2 Q	3 Q	4 Q	Total
New	522	414	391	361	1,688
Withdrawal	(100)	(157)	(89)	(95)	(441)

Pharmaceutical Manufacturing and Distribution Business / Pharmaceutical Logistics Business






Steady expansion of sales channels has led to a significant increase in the number of transacting pharmacies.

New transacting pharmacies **6,993** (+1,822 vs. YoY)

No. of products adjusted for shipment as of June 30: 9 products / 4 ingredients

■ Net Sales and No. of transacting pharmacies




^{*} Total pharmacies that have actually transacted business since April of each year.



Reached 2,000 transacting pharmacies in the 1st year since the company's establishment. In addition, started daily delivery of pharmaceutical products this fiscal year.

New transacting pharmacies **2,408店** (+836店 vs. YoY)

■ Net Sales and No. of transacting pharmacies



^{*} Cumulative No. of pharmacies that have transacted business since April 2025.

Digital Shift Business






Official LINE Account

- 1.57 million users have registered and 6,626 pharmacies have installed the service.
- No. of installed pharmacies exceeded the plan, and the No. of LINE registered users accelerated due to increased use of the medical interview function.

■ No. of users registrations and installed pharmacies



■ Focus on distributing and delivering information for patients and pharmacies

- •For patients: disseminate health information via SNS and "Connected Pharmacy Navi".
- For pharmacies: distribute webinars and "Useful columns" within the pharmacy website.
- → Aim to Raise Awareness and Promote Use of Pharmacy DX and Tsunagaru Pharmacy.



From "Useful Columns" on the Tsunagaru Pharmacy website



Earnings Forecast for the FY3/2026:

Consolidated Forecast





Although wage increases will be implemented in the fiscal year ending March 31, 2026, we forecast an increase in both sales and profit due to an increase in the number of pharmaceutical network members, an increase in the number of prescriptions filled, and sales expansion of generics.

(Unit: million yen)	FY3/2025 Results	FY3/2026 Forecast	Change	Change (%)
Net sales	122,387	125,500	+3,112	+2.5%
EBITDA Profit margin	6,569 _{5.4%}	6,890 _{5.5%}	+320 0.1pt	+4.9%
Operating profit Profit margin	3,154 _{2.6%}	3,400 _{2.7%}	+245 0.1pt	+7.8%
Ordinary profit Profit margin	3,162 2.6%	3,200 _{2.5%}	+37 (0.0pt)	+1.2%
Profit attributable to owners of parent Profit margin	1,262 1.0%	1,300 1.0%	+37 (0.0pt)	+3.0%
Earnings per share (Yen)	43.20	44.48	+1.28	_

Earnings Forecast for the FY3/2026:

Forecast by Segment





■ Net Sales (Unit: million yen)		FY3/2025 Results	FY3/2026 Forecast	Change	Change (%)		
Net Sales		122,387	125,500	+3,112	+2.5%		
	Community Pharmacy Network Segment *	116,968	120,099	+3,131	+2.7%		
	Leasing and Facility Related Segment Meals Catering Segment Home Visit Nursing Segment	6,171	6,226	+55	+0.9%		
	Adjustments	(751)	(826)	(74)	_		
■ Operating Profit (Unit: million yen) The second line is profit margin							
Segment Profit		3,154 _{2.6%}	3,400 _{2.7%}	+245 0.1pt	+7.8%		
	Community Pharmacy Network Segment *	5,626 4.8%	5,973 5.0%	+346 0.2pt	+6.2%		
	Leasing and Facility Related Segment Meals Catering Segment Home Visit Nursing Segment	171 2.8%	217 3.5%	+46 0.7pt	+27.0%		
	Adjustments	(2,644)	(2,791)	(146) -	_		

^{*} Community Pharmacy Business, Pharmacy Support Businesses (Pharmaceutical Network Business, Pharmaceutical Manufacturing and Distribution Business, Pharmaceutical Logistics Business, Digital Shift Business)



Sustainability: Governance Structure



Basic Policy on Sustainability

~ Aiming to improve the quality of life (QOL) of local residents and contribute to a sustainable society ~

We are committed to promoting community health and establishing comprehensive medical care and lifestyle support that allows residents to live confidently in Japan's super-aged society.

By collaborating closely with our stakeholders, we will tackle environmental and social challenges through our business operations, working to achieve both societal sustainability and our own continued growth.

Sustainability Governance Structure

Sustainability Committee

Discuss cross-functional issues across businesses and departments. Operated under the supervision of the Board of Directors as a forum for deliberating and deciding on important matters related to sustainability.

- <Role of the Committee>
- Formulation of basic policies
- ·Identification of materiality (priority issues) for our corporate group
- •Identification of risks and opportunities, setting and review of objectives
- Coordination between departments and monitoring of progress
- •Consultation and decision-making regarding information disclosure, etc.

Board of Directors

Sustainability Committee

Chairperson:

President & CEO

Vice Chairperson:

Representative Director & Executive Vice President

Committee member:

Executive Director

Each department (including group companies)

Sustainability:

Contributing to the community through inventory sharing systems



LINCLE Regional Version

Establishment of an area network to share information on dispensing performance for groups such as pharmacists' associations, using in-house developed dispensing performance sharing system. Smoothly facilitates inter-pharmacy coordination to ensure a stable supply of pharmaceuticals and reduce the number of urgent deliveries.







MEDICAL SYSTEM NETWORK Co., Ltd.

https://www.msnw.co.jp/eng

MSNW

Search

[Contact us] Corporate Management Division

E-mail: info@msnw.co.jp